{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T05:23:00Z","timestamp":1794201780721,"version":"4.8.0"},"reference-count":32,"publisher":"Walter de Gruyter GmbH","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2025-1464_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Low mitochondrial DNA copy number (mtCN) in leukocytes is a predictor of all-cause mortality, independent of age and sex. For malignant diseases, results about the prognostic value of leukocyte mtCN have been conflicting. Aim of the present study was to analyze the prognostic value of mtCN for long-term prostate cancer survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-1464_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Blood samples of prostate cancer patients were obtained before initiation of radiotherapy. Relative mtCN was determined by a quantitative polymerase chain reaction method in 662 patients with prostate cancer. Main outcome was overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-1464_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During a follow-up time of 120\u00a0months, 218 (32.9\u202f%) patients died. In a univariate Cox regression analysis, higher mtCN z-score was significantly associated with lower overall mortality (hazard ratio 0.83, 95\u202f% confidence interval 0.72\u20130.96; p=0.009). In a multivariate Cox regression model including age at diagnosis, androgen deprivation therapy, and risk group (based on PSA level, GS, and T stage), higher mtCN z-score remained a significant predictor of lower overall mortality (hazard ratio 0.85, 95\u202f% confidence interval 0.74\u20130.98; p=0.029).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-1464_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>High leukocyte mtCN predicts better overall survival in patients with prostate cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2025-1464","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T20:16:02Z","timestamp":1776456962000},"page":"1767-1772","source":"Crossref","is-referenced-by-count":0,"title":["Mitochondrial DNA copy number in leukocytes predicts long-term survival in prostate cancer"],"prefix":"10.1515","volume":"64","author":[{"given":"Tanja","family":"Langsenlehner","sequence":"first","affiliation":[{"name":"Department of Therapeutic Radiology and Oncology , Medical University of Graz , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Paal","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Radiology and Oncology , Medical University of Graz , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Maria","family":"Thurner","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Radiology and Oncology , Medical University of Graz , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Langm\u00fcller","sequence":"additional","affiliation":[{"name":"Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Sternat","sequence":"additional","affiliation":[{"name":"Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6199-4382","authenticated-orcid":false,"given":"Wilfried","family":"Renner","sequence":"additional","affiliation":[{"name":"Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"2026110905014435893_j_cclm-2025-1464_ref_001","doi-asserted-by":"crossref","unstructured":"Yu, M. Circulating cell-free mitochondrial DNA as a novel cancer biomarker: opportunities and challenges. Mitochondrial DNA 2012;23:329\u201332. https:\/\/doi.org\/10.3109\/19401736.2012.696625.","DOI":"10.3109\/19401736.2012.696625"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_002","doi-asserted-by":"crossref","unstructured":"Reznik, E, Miller, ML, \u015eenbabao\u011flu, Y, Riaz, N, Sarungbam, J, Tickoo, SK, et al.. Mitochondrial DNA copy number variation across human cancers. eLife 2016;5:e10769. https:\/\/doi.org\/10.7554\/elife.10769.","DOI":"10.7554\/eLife.10769"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_003","doi-asserted-by":"crossref","unstructured":"Ashar, FN, Moes, A, Moore, AZ, Grove, ML, Chaves, PHM, Coresh, J, et al.. Association of mitochondrial DNA levels with frailty and all-cause mortality. J\u00a0Mol Med (Berl) 2015;93:177\u201386. https:\/\/doi.org\/10.1007\/s00109-014-1233-3.","DOI":"10.1007\/s00109-014-1233-3"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_004","doi-asserted-by":"crossref","unstructured":"Xu, E, Sun, W, Gu, J, Chow, WH, Ajani, JA, Wu, X. Association of mitochondrial DNA copy number in peripheral blood leukocytes with risk of esophageal adenocarcinoma. Carcinogenesis 2013;34:2521\u20134. https:\/\/doi.org\/10.1093\/carcin\/bgt230.","DOI":"10.1093\/carcin\/bgt230"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_005","doi-asserted-by":"crossref","unstructured":"Yang, K, Li, X, Forman, MR, Monahan, PO, Graham, BH, Joshi, A, et al.. Pre-diagnostic leukocyte mitochondrial DNA copy number and colorectal cancer risk. Carcinogenesis 2019;40:1462\u20138. https:\/\/doi.org\/10.1093\/carcin\/bgz159.","DOI":"10.1093\/carcin\/bgz159"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_006","doi-asserted-by":"crossref","unstructured":"Gentiluomo, M, Katzke, VA, Kaaks, R, Tj\u00f8nneland, A, Severi, G, Perduca, V, et al.. Mitochondrial DNA copy-number variation and pancreatic cancer risk in the prospective EPIC cohort. Cancer Epidemiol Biomarkers Prev 2020;29:681\u20136. https:\/\/doi.org\/10.1158\/1055-9965.epi-19-0868.","DOI":"10.1158\/1055-9965.EPI-19-0868"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_007","doi-asserted-by":"crossref","unstructured":"He, X, Qu, F, Zhou, F, Zhou, X, Chen, Y, Guo, X, et al.. High leukocyte mtDNA content contributes to poor prognosis through ROS-mediated immunosuppression in hepatocellular carcinoma patients. Oncotarget 2016;7:22834\u201345. https:\/\/doi.org\/10.18632\/oncotarget.8071.","DOI":"10.18632\/oncotarget.8071"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_008","doi-asserted-by":"crossref","unstructured":"Qu, F, Chen, Y, Wang, X, He, X, Ren, T, Huang, Q, et al.. Leukocyte mitochondrial DNA content: a novel biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Carcinogenesis 2015;36:543\u201352. https:\/\/doi.org\/10.1093\/carcin\/bgv042.","DOI":"10.1093\/carcin\/bgv042"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_009","doi-asserted-by":"crossref","unstructured":"Zhang, W, Lin, S, Zeng, B, Chen, X, Chen, L, Chen, M, et al.. High leukocyte mitochondrial DNA copy number contributes to poor prognosis in breast cancer patients. BMC Cancer 2023;23:377. https:\/\/doi.org\/10.1186\/s12885-023-10838-x.","DOI":"10.1186\/s12885-023-10838-x"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_010","doi-asserted-by":"crossref","unstructured":"Zhou, W, Zhu, M, Gui, M, Huang, L, Long, Z, Wang, L, et al.. Peripheral blood mitochondrial DNA copy number is associated with prostate cancer risk and tumor burden. PLoS One 2014;9:e109470. https:\/\/doi.org\/10.1371\/journal.pone.0109470.","DOI":"10.1371\/journal.pone.0109470"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_011","doi-asserted-by":"crossref","unstructured":"Xu, J, Chang, WS, Tsai, CW, Bau, DT, Davis, JW, Thompson, TC, et al.. Mitochondrial DNA copy number in peripheral blood leukocytes is associated with biochemical recurrence in prostate cancer patients in African Americans. Carcinogenesis 2020;41:267\u201373. https:\/\/doi.org\/10.1093\/carcin\/bgz139.","DOI":"10.1093\/carcin\/bgz139"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_012","doi-asserted-by":"crossref","unstructured":"Langsenlehner, T, Langsenlehner, U, Renner, W, Kapp, KS, Krippl, P, Hofmann, G, et al.. The Glu228Ala polymorphism in the ligand binding\u00a0domain of death receptor 4 is associated with increased\u00a0risk\u00a0for prostate cancer metastases. Prostate 2008;68:264\u20138. https:\/\/doi.org\/10.1002\/pros.20682.","DOI":"10.1002\/pros.20682"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_013","doi-asserted-by":"crossref","unstructured":"Langsenlehner, T, Renner, W, Gerger, A, Hofmann, G, Thurner, EM, Kapp, KS, et al.. Impact of VEGF gene polymorphisms and haplotypes on radiation-induced late toxicity in prostate cancer patients. Strahlenther Onkol 2011;187:784\u201391. https:\/\/doi.org\/10.1007\/s00066-011-1106-4.","DOI":"10.1007\/s00066-011-1106-4"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_014","doi-asserted-by":"crossref","unstructured":"Trummer, O, Langsenlehner, U, Krenn-Pilko, S, Pieber, TR, Obermayer-Pietsch, B, Gerger, A, et al.. Vitamin D and prostate cancer prognosis: a Mendelian randomization study. World J Urol 2016;34:607\u201311. https:\/\/doi.org\/10.1007\/s00345-015-1646-9.","DOI":"10.1007\/s00345-015-1646-9"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_015","doi-asserted-by":"crossref","unstructured":"Gr\u00f6ber, U, Holzhauer, P, Kisters, K, Holick, MF, Adamietz, IA. Micronutrients in oncological intervention. Nutrients 2016;8:163. https:\/\/doi.org\/10.3390\/nu8030163.","DOI":"10.3390\/nu8030163"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_016","doi-asserted-by":"crossref","unstructured":"Reuther, S, Szymczak, S, Raabe, A, Borgmann, K, Ziegler, A, Petersen, C, et al.. Association between SNPs in defined functional pathways and risk of early or late toxicity as well as individual radiosensitivity. Strahlenther Onkol 2015;191:59\u201366. https:\/\/doi.org\/10.1007\/s00066-014-0741-y.","DOI":"10.1007\/s00066-014-0741-y"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_017","doi-asserted-by":"crossref","unstructured":"Langsenlehner, T, Thurner, EM, Renner, W, Gerger, A, Kapp, KS, Langsenlehner, U. Association of genetic variants in VEGF-A with clinical recurrence in prostate cancer patients treated with definitive radiotherapy. Strahlenther Onkol 2014;190:364\u20139. https:\/\/doi.org\/10.1007\/s00066-013-0503-2.","DOI":"10.1007\/s00066-013-0503-2"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_018","doi-asserted-by":"crossref","unstructured":"Thurner, EM, Krenn-Pilko, S, Langsenlehner, U, Renner, W, Gerger, A, Kapp, KS, et al.. Association of genetic variants in apoptosis genes FAS and FASL with radiation-induced late toxicity after prostate cancer radiotherapy. Strahlenther Onkol 2014;190:304\u20139. https:\/\/doi.org\/10.1007\/s00066-013-0485-0.","DOI":"10.1007\/s00066-013-0485-0"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_019","doi-asserted-by":"crossref","unstructured":"Langsenlehner, T, Langsenlehner, U, Renner, W, Krippl, P, Mayer, R, Wascher, TC, et al.. Single nucleotide polymorphisms and\u00a0haplotypes\u00a0in the gene for vascular endothelial growth\u00a0factor\u00a0and\u00a0risk of prostate cancer. Eur J Cancer 2008;44:1572\u20136. https:\/\/doi.org\/10.1016\/j.ejca.2008.04.021.","DOI":"10.1016\/j.ejca.2008.04.021"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_020","doi-asserted-by":"crossref","unstructured":"Langsenlehner, T, Renner, W, Gerger, A, Hofmann, G, Thurner, EM, Kapp, KS, et al.. Association between single nucleotide polymorphisms in the gene for XRCC1 and radiation-induced late toxicity in prostate cancer patients. Radiother Oncol 2011;98:387\u201393. https:\/\/doi.org\/10.1016\/j.radonc.2011.01.021.","DOI":"10.1016\/j.radonc.2011.01.021"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_021","doi-asserted-by":"crossref","unstructured":"Mohler, J, Bahnson, RR, Boston, B, Busby, JE, D\u2019Amico, A, Eastham, JA, et al.. NCCN clinical practice guidelines in oncology: prostate cancer. J\u00a0Natl Compr Cancer Netw 2010;8:162\u2013200. https:\/\/doi.org\/10.6004\/jnccn.2010.0012.","DOI":"10.6004\/jnccn.2010.0010"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_022","doi-asserted-by":"crossref","unstructured":"Schemper, M, Smith, TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343\u20136. https:\/\/doi.org\/10.1016\/0197-2456(96)00075-x.","DOI":"10.1016\/0197-2456(96)00075-X"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_023","doi-asserted-by":"crossref","unstructured":"Buck, MD, O\u2019Sullivan, D, Pearce, EL. T\u00a0cell metabolism drives immunity. J\u00a0Exp Med 2015;212:1345\u201360. https:\/\/doi.org\/10.1084\/jem.20151159.","DOI":"10.1084\/jem.20151159"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_024","doi-asserted-by":"crossref","unstructured":"Vyas, S, Zaganjor, E, Haigis, MC. Mitochondria and cancer. Cell 2016;166:555\u201366. https:\/\/doi.org\/10.1016\/j.cell.2016.07.002.","DOI":"10.1016\/j.cell.2016.07.002"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_025","doi-asserted-by":"crossref","unstructured":"Aggarwal, BB, Shishodia, S, Sandur, SK, Pandey, MK, Sethi, G. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006;72:1605\u201321. https:\/\/doi.org\/10.1016\/j.bcp.2006.06.029.","DOI":"10.1016\/j.bcp.2006.06.029"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_026","doi-asserted-by":"crossref","unstructured":"Mills, EL, Kelly, B, Logan, A, Costa, ASH, Varma, M, Bryant, CE, et al.. Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. Cell 2016;167:457\u201370. https:\/\/doi.org\/10.1016\/j.cell.2016.08.064.","DOI":"10.1016\/j.cell.2016.08.064"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_027","doi-asserted-by":"crossref","unstructured":"Sharma, N, Pasala, MS, Prakash, A. Mitochondrial DNA: epigenetics and environment. Environ Mol Mutagen 2019;60:668\u201382. https:\/\/doi.org\/10.1002\/em.22319.","DOI":"10.1002\/em.22319"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_028","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Ot\u00edn, C, Blasco, MA, Partridge, L, Serrano, M, Kroemer, G. The hallmarks of aging. Cell 2013;153:1194\u2013217. https:\/\/doi.org\/10.1016\/j.cell.2013.05.039.","DOI":"10.1016\/j.cell.2013.05.039"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_029","doi-asserted-by":"crossref","unstructured":"H\u00e4ggstr\u00f6m, C, Stocks, T, Ulmert, D, Bj\u00f8rge, T, Ulmer, H, Hallmans, G, et al.. Prospective study on metabolic factors and risk of prostate cancer. Cancer 2012;118:6199\u2013206. https:\/\/doi.org\/10.1002\/cncr.27677.","DOI":"10.1002\/cncr.27677"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_030","doi-asserted-by":"crossref","unstructured":"Calle, EE, Rodriguez, C, Walker-Thurmond, K, Thun, MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N\u00a0Engl J Med 2003;348:1625\u201338. https:\/\/doi.org\/10.1056\/nejmoa021423.","DOI":"10.1056\/NEJMoa021423"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_031","doi-asserted-by":"crossref","unstructured":"Harborg, S, Kj\u00e6rgaard, KA, Thomsen, RW, Borgquist, S, Cronin-Fenton, D, Hjorth, CF. New Horizons: Epidemiology of obesity, diabetes mellitus, and cancer prognosis. J\u00a0Clin Endocrinol Metab 2024;109:924\u201335. https:\/\/doi.org\/10.1210\/clinem\/dgad450.","DOI":"10.1210\/clinem\/dgad450"},{"key":"2026110905014435893_j_cclm-2025-1464_ref_032","doi-asserted-by":"crossref","unstructured":"Wallace, DC. Mitochondria and cancer. Nat Rev Cancer 2012;12:685\u201398. https:\/\/doi.org\/10.1038\/nrc3365.","DOI":"10.1038\/nrc3365"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-1464\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-1464\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T05:03:32Z","timestamp":1794200612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-1464\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4,13]]},"published-print":{"date-parts":[[2026,7,24]]}},"alternative-id":["10.1515\/cclm-2025-1464"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2025-1464","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]}}}